Geraldine Navarro is a Rheumatology/Immunology physician affiliated with University of California, Los Angeles. OpenAlex indexes 6 publications with 244 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
28.8%TNF inhibitor9.2%Humira(Cf) Pen73%Cimzia16%Simponi11%Part D<11 patientsFolate Analog Metabolic Inhibitor9.2%Methotrexate100%Part D≥35 patients+ 5 more classes in this area
Metabolism & gastrointestinal
21%Corticosteroid12.6%Prednisone100%Part D≥59 patientsAminosalicylate4.7%Sulfasalazine Dr54%Sulfasalazine46%Part D<11 patients+ 3 more classes in this area
Musculoskeletal
17.7%Xanthine oxidase inhibitor4.8%Allopurinol100%Part D≥23 patientsgamma-Aminobutyric Acid-ergic Agonist4.4%Baclofen100%Part D≥24 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The 2023 ACR/<scp>EULAR</scp> Classification Criteria for Calcium Pyrophosphate Deposition Disease
Arthritis & Rheumatology
2023 - The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease
Annals of the Rheumatic Diseases
2023 - Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients
Clinical Rheumatology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Gregg Fonarow, MD
University of California, Los Angeles
Dennis Slamon, MD
University of California, Los Angeles
Tomas Ganz, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”